A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)

PURPOSE: Preclinical and clinical data have shown promise in using antiangiogenic agents to treat malignant pleural mesothelioma (MPM). We conducted this phase II study to evaluate the efficacy and toxicity of single‐agent pazopanib in patients with MPM. MATERIALS AND METHODS: Patients with MPM who...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Parikh, Kaushal, Mandrekar, Sumithra J., Allen‐Ziegler, Katie, Esplin, Brandt, Tan, Angelina D., Marchello, Benjamin, Adjei, Alex A., Molina, Julian R.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Assuntos:
Lung Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288653/
https://ncbi.nlm.nih.gov/pubmed/31872928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0574
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares